SELLAS Life Sciences (SLS) Fundamental Analysis: Revenue, Earnings & Valuation

1.78 / 10

Underperform

Fundamental analysis rates SLS as Underperform with a 1.8/10 score. Positive drivers include accounts‑receivable turnover and interest coverage, but fixed‑asset turnover and tax‑to‑profit ratios drag performance. Composite fund score is only 1.78, indicating constrained valuation despite modest revenue‑MV advantage.

Analysis Checks(6/10)

Revenue-MV

Value-0.28

Score3/3

Weight66.25%

1M Return8.83%

Total operating revenue (YoY growth rate %)

Value134.75

Score2/3

Weight3.52%

1M Return0.58%

Inventory turnover ratio

Value106.57

Score3/3

Weight-3.76%

1M Return-0.67%

Accounts receivable turnover ratio

Value23.61

Score2/3

Weight-3.73%

1M Return-0.65%

PB-ROE

Value1.77

Score0/3

Weight27.24%

1M Return3.80%

Income tax / Total profit (%)

Value22.35

Score0/3

Weight-8.47%

1M Return-1.54%

Fixed assets turnover ratio

Value9771.06

Score1/3

Weight-6.98%

1M Return-1.28%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight-4.20%

1M Return-0.73%

Cost of sales ratio (%)

Value57.03

Score2/3

Weight-4.13%

1M Return-0.74%

Asset-MV

Value-0.48

Score0/3

Weight34.26%

1M Return4.88%

Is SLS fundamentally strong?

SLS scores 1.78/10 on fundamentals and holds a Premium valuation at present. Backed by its -66.88% ROE, 0.00% net margin, -33.39 P/E ratio, 12.66 P/B ratio, and 50.00% earnings growth, these metrics solidify its Underperform investment rating.